ANAHEIM,
Calif., July 25, 2023 /PRNewswire/ -- Beckman
Coulter Diagnostics, a clinical diagnostics leader, received FDA
clearance for its new DxC 500 AU Chemistry Analyzer, an automated
chemistry analyzer, expanding the company's clinical chemistry
offering and demonstrating ongoing commitment to product innovation
in the in vitro diagnostic industry. Designed for
small-to-medium-sized laboratories, the DxC 500 AU Chemistry
Analyzer is one of several recent Beckman Coulter solutions
designed to optimize laboratory workflows and support critical
clinical decisions.
The DxC 500 AU Chemistry Analyzer uses standardized assays and
reagents found across Beckman Coulter's portfolio of AU clinical
chemistry analyzers. Using standardized assays and reagents
facilitates timely and accurate patient results for both
independent laboratories and those part of integrated networks,
delivering consistent, harmonized results across AU platforms for
clinical decision-making and patient outcomes.
"We are pleased to expand our offering of reliable clinical
chemistry series," said Kathleen
Orland, Senior Vice President, Business Unit, General
Manager Chemistry and Immunoassay for Beckman Coulter Diagnostics.
"In addition to commutable patient results across low-to
high-volume chemistry platforms, application of the same reagents
has a positive impact on inventory and cost across a health
system."
"The Beckman Coulter DxC 500 AU Clinical Chemistry Analyzer,
assessed by Six Sigma metrics, meets and/or exceeds the many
demands of CLIA 2024 performance specifications," stated
Sten Westgard, Director of Client
Services and Technology for Westgard QC.
Diagnostic testing guides 70% of medical decisions1
and with increased demand for improved accuracy and reliability of
results, the DxC 500 AU Chemistry Analyzer's broad menu of 120-plus
assays has been independently and objectively verified for quality
performance, supporting confidence in result integrity.
The DxC 500 AU Chemistry Analyzer is for in vitro diagnostic use
only.
Follow and connect with Beckman Coulter Diagnostics
via LinkedIn, Twitter, and Facebook.
About Beckman Coulter. Inc.
A global leader in advanced diagnostics, Beckman Coulter has
challenged convention to elevate the diagnostic laboratory's role
in improving patient health for more than 80 years. Our mission is
to Relentlessly Reimagine Healthcare, One Diagnosis at a
Time – and we do this by applying the power of science,
technology and the passion and creativity of our teams. Our
diagnostic solutions are used in complex clinical testing, and are
found in hospitals, reference laboratories and physician office
settings around the globe. We exist to deliver smarter, faster
diagnostic solutions that move the needle forward from what's now
to what's next. We seek to accelerate care with an extensive
clinical menu, scalable lab automation technologies, insightful
clinical informatics, and optimize lab performance services.
Beckman Coulter is part of the Danaher Corporation (NYSE:DHR)
family of global science and technology companies. Headquartered in
Brea, Calif., it has more than
11,000 global team members.
1
https://www.cdc.gov/csels/dls/strengthening-clinical-labs.html
©2023 Beckman Coulter. All rights reserved. Beckman Coulter, the
stylized logo, and the Beckman Coulter product and service marks
mentioned herein are trademarks or registered trademarks of Beckman
Coulter, Inc. in the United States
and other countries. 2023-11985
View original content to download
multimedia:https://www.prnewswire.com/news-releases/beckman-coulter-receives-fda-clearance-for-dxc-500-au-chemistry-analyzer-expanding-portfolio-with-proven-six-sigma-performance-301884673.html
SOURCE Beckman Coulter, Inc.
